Literature DB >> 28400618

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

P Kongtim1, K Adekola1, D R Milton2, R Ramlal1, A Jimenez1, J Chen1, G Rondon1, S Ahmed1, P Kebriaei1, O Betul1, C M Hosing1, U Popat1, I Khouri1, E Jabbour3, J E Cortes3, H M Kantarjian3, R E Champlin1, S O Ciurea1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28400618      PMCID： PMC6192023          DOI： 10.1038/leu.2017.118

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

Authors:  H Jiang; L-P Xu; D-H Liu; K-Y Liu; S-S Chen; B Jiang; Q Jiang; H Chen; Y-H Chen; W Han; X-H Zhang; Y Wang; J-Z Wang; F-R Wang; Y-Z Qin; Y-Y Lai; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-07-21       Impact factor: 5.483

2.  Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Authors:  Antonio Di Stasi; Denái R Milton; L M Poon; Amir Hamdi; Gabriela Rondon; Julianne Chen; Sai R Pingali; Marina Konopleva; Piyanuch Kongtim; Amin Alousi; Muzaffar H Qazilbash; Sairah Ahmed; Qaiser Bashir; Gheath Al-atrash; Betul Oran; Chitra M Hosing; Partow Kebriaei; Uday Popat; Elizabeth J Shpall; Dean A Lee; Marcos de Lima; Katayoun Rezvani; Issa F Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Authors:  Francesca Palandri; Fausto Castagnetti; Giuliana Alimena; Nicoletta Testoni; Massimo Breccia; Simona Luatti; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Bruno Martino; Luciano Levato; Serena Merante; Anna Maria Liberati; Fabrizio Pane; Giuseppe Saglio; Daniele Alberti; Giovanni Martinelli; Michele Baccarani; Gianantonio Rosti
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

6.  Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Authors:  Partow Kebriaei; Michelle A Detry; Sergio Giralt; Antonio Carrasco-Yalan; Athanasios Anagnostopoulos; Daniel Couriel; Issa F Khouri; Paolo Anderlini; Chitra Hosing; Amin Alousi; Richard E Champlin; Marcos de Lima
Journal:  Blood       Date:  2007-07-25       Impact factor: 22.113

7.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

8.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

9.  Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

Authors:  Didier Blaise; Sabine Fürst; Roberto Crocchiolo; Jean El-Cheikh; Angela Granata; Samia Harbi; Reda Bouabdallah; Raynier Devillier; Stephania Bramanti; Claude Lemarie; Christophe Picard; Christian Chabannon; Pierre-Jean Weiller; Catherine Faucher; Bilal Mohty; Norbert Vey; Luca Castagna
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-01       Impact factor: 5.742

Review 10.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544
View more
  1 in total

Review 1.  Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.

Authors:  Michele Baccarani; Francesca Bonifazi; Simona Soverini; Fausto Castagnetti; Gabriele Gugliotta; Wael Saber; Noel Estrada-Merly; Gianantonio Rosti; Robert Peter Gale
Journal:  Leukemia       Date:  2022-03-25       Impact factor: 12.883
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.